Bruker set to bring chromatography-free diagnostics to the masses

Jeff Zonderman, Vice President of Bruker Applied Mass Spectrometry, unveils major strides in clinical diagnostics with the acquisition of RECIPE, a leading provider of mass spectrometry diagnostic kits for small molecule analysis. Combined with Bruker’s DART (Direct Analysis in Real Time) technology, this move enables the development of fully integrated, chromatography-free mass spectrometry workflows tailored to clinical laboratories.

These innovations—centered around the EVOQ DART TQ+ system—promise higher throughput, reduced solvent use, and simplified workflows, making mass spectrometry more accessible to a wider range of labs. Clinical areas of focus include therapeutic drug monitoring, toxicology, and drugs of abuse, with Bruker working toward a future where mass spectrometry functions more like a traditional clinical analyzer.

With a proven track record in simplifying complex instrumentation—like the industry-leading MALDI Biotyper—Bruker is once again breaking down barriers to clinical adoption. By removing chromatography from the equation, the company is delivering greener, faster, and easier diagnostics for the real-world needs of today’s laboratories.

Watch to learn how Bruker is reshaping the future of clinical mass spectrometry.